ATTO Attovia Therapeutics, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Attovia Therapeutics, Inc. reported revenue of $450K, net income of −$20.7M and diluted EPS of −$4.88.
ATTO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $450K, net income −$20.7M, EPS −$4.88
- Quarter ended Mar 31, 2026: revenue n/a, net income −$18.7M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$14.4M, EPS −$3.71
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.2M, EPS n/a
ATTO balance sheet
- Jun 30, 2026: cash $32.8M, total assets $128M, total liabilities $15.6M, shareholders' equity −$145M
- Dec 31, 2025: cash $40.2M, total assets $166M, total liabilities $15.1M, shareholders' equity −$107M